Annotation Detail

Information
Associated Genes
FGFR1
Associated Variants
FGFR1 AMPLIFICATION ( ENST00000425967.8 )
FGFR1 AMPLIFICATION ( ENST00000425967.8 )
Associated Disease
lung squamous cell carcinoma
Source Database
CIViC Evidence
Description
Phase 1 study of FGFR-inhibitor BGJ398 in advanced cancer with FGFR-aberrations. In the subgroup of FGFR1-amplified NSCLC, 36 patients were treated at doses >100mg and disease control was achieved in 50% of patients (4 PR and 14 SD) with 6 patients receiving treatment after 16 weeks.
Variant Origin
N/A
Variant Origin
N/A
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1908
Gene URL
https://civic.genome.wustl.edu/links/genes/1885
Variant URL
https://civic.genome.wustl.edu/links/variants/267
Rating
3
Evidence Type
Predictive
Disease
Lung Squamous Cell Carcinoma
Evidence Direction
Supports
Drug
Infigratinib
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
27870574
Drugs
Drug NameSensitivitySupported
InfigratinibSensitivitytrue